Skip to Content

Zeev Estrov, MD

Present Title & Affiliation

Primary Appointment

Professor of Medicine and Internist, Director of Hematopoiesis Research, Department of Leukemia, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Member, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1400 Holcombe Boulevard
Unit Number: 428
Houston, TX 77030
Room Number: FC4.2048

Education & Training

Degree-Granting Education

1975 Tel-Aviv University School of Medicine, Tel-Aviv, Israel, MD, (Magna Cum Laude), (Doctor of Medicine)

Postgraduate Training

1992-1995 Fellowship in Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
1984-1987 Fellow, Hematology/Oncology and Hematopoiesis Research, The Hospital for Sick Children, University of Toronto, and The Hospital for Sick Children Research Institute, Toronto, Canada
1975-1980 Clinical Residency, Internal Medicine, Kaplan Hospital Rehovot, Weizmann Institute of Science, Rehovot, Israel
1973-1974 Clinical Internship, Kaplan Hospital, Rehovot, Israel

Board Certifications

8/1998 American Board of Internal Medicine
6/1981 The Israeli Board of Internal Medicine


Institutional Committee Activities

Member, Conflict Management Committee, 2007-2008
Member, Institutional Research Grants Program Study Review Committee for Basic Research Projects, 2005-2008
Member, Institutional Review Board (IRB), 2000-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Faderl S, Estrov Z. Hematopoietic recovery following induction therapy of acute leukemias: prognostic implications and a new look at the definition of remission. Leuk Lymphoma 45(1):67-71, 1/2004. PMID: 15061199.
2. Faderl S, Ferrajoli A, Harris D, Van Q, Kantarjian HM, Estrov Z. Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells. Leuk Res 31(1):91-5, 1/2007. e-Pub 7/7/2006. PMID: 16828865.
3. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109(1):52-7, 1/1/2007. e-Pub 8/1/2006. PMID: 16882708.
4. Quintás-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S, Cortes J. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 109(2):248-55, 1/15/2007. PMID: 17154172.
5. Kornblau SM, Banker DE, Stirewalt D, Shen D, Lemker E, Verstovsek S, Estrov Z, Faderl S, Cortes J, Beran M, Jackson CE, Chen W, Estey E, Appelbaum FR. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high dose Ara-C: A Phase 1 study. Blood 109(7):2999-06, 4/1/2007. PMCID: PMC1852228.
6. Aribi A, Bueso-Ramos C, Estey E, Estrov Z, O'Brien S, Giles F, Faderl S, Thomas D, Kebriaei P, Garcia-Manero G, Pierce S, Cortes J, Kantarjian H, Ravandi F. Biphenotypic acute leukemia: a case series. Br J Haematol 138(2):213-6, 7/2007. PMID: 17593028.
7. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Garcia-Manero G. Safety and clinical activity of the combination of 5-azacytidine, valproic acid and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110(7):2302-8, 10/1/2007. e-Pub 6/27/2007. PMID: 17596541.
8. Verstovsek S, Manshouri T, Quintás-Cardama A, Harris D, Cortes J, Giles FJ, Kantarjian H, Priebe W, Estrov Z. WP1066, A novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res 14(3):788-96, 2/1/2008. PMID: 18245540.
9. Ma W, Kantarjian H, O'Brien S, Jilani I, Zhang X, Estrov Z, Ferrajoli A, Keating M, Giles F, Albitar M. Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia. Cancer 112(6):1306-12, 3/15/2008. PMID: 18224667.
10. Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, Newsome WM, Miller WH, Rousseau C, Kalita A, Bonfils C, Dubay M, Patterson TA, Li Z, Besterman JM, Reid G, Laille E, Martell RE, Minden M. Phase I study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 112(4):981-9, 8/15/2008. e-Pub 5/21/2008. PMID: 18495956.
11. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 26(2):196-203, 1/2008. PMID: 18182662.
12. Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 100(3):184-98, 2/2008. e-Pub 1/2008. PMID: 18230792.
13. Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as frontline therapy for patients age >= 60 years with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 112(5):1638-1645, 9/1/2008. e-Pub 6/18/2008. PMID: 18565853.
14. Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S, Wierda WG, Estrov Z, Faderl S, Cohen EN, Li C, Reuben JM, Keating MJ. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111(11):5291-7, 6/1/2008. e-Pub 3/11/2008. PMID: 18334676.
15. Borthakur G, Alvarado Y, Ravandi-Kashani F, Cortes J, Estrov Z, Faderl S, Ivy P, Bueso-Ramos C, Nebiyou Bekele B, Giles F. Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies. Cancer 113(2):360-6, 7/15/2008. PMID: 18473351.
16. Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther 7(3):464-73, 3/2008. PMID: 18347134.
17. Manshouri T, Quintás-Cardama A, Nussenzveig RH, Gaikwad A, Estrov Z, Prchal J, Cortes JE, Kantarjian HM, Verstovsek S. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci 99(6):1265-73, 6/2008. PMID: 18482053.
18. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H. Effective treatment of acute promyelocytic leukemia with all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 27(4):504-10, 2/2009. e-Pub 12/2008. PMID: 19075265.
19. Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F, Estrov Z, Borthakur G, Kwari M, Kantarjian HM. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 113(8):2090-2091, 10/15/2008. PMID: 18756533.
20. Estrov Z, Freedman MH. Juvenile chronic myelogenous leukemia(JCML): In vitro characterization of the disease. First Annual Meeting of the Israel Society of Pediactric Hematology-Oncology, Jerusalem, 2/1988.
21. Bruey JM, Kantarjian H, Estrov Z, Zhang Z, Ma W, Albitar F, Abdool A, Thomas D, Yeh C, O'Brien S, Albitar M. Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia. Leuk Res 34(2):173-6, 2/2010. e-Pub 8/12/2009. PMID: 19679351.
22. Verma D, Kantarjian H, Shan J, O'Brien S, Estrov Z, Garcia-Manero G, Koller C, Borthakur G, Cortes J. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on a second generation tyrosine kinase inhibitor therapy. Cancer 116(11):2673-81, 6/2010. PMID: 20499401.
23. Quintás-Cardama A, Manshouri T, Estrov Z, Harris D, Zhang Y, Gaikwad A, Kantarjian HM, Verstovsek S. Preclinical characterization of antiprimod, a novel Jak2 and Jak3 inhibitor. Invest New Drugs 29(5):818-26, 10/2011. e-Pub 4/2010. PMID: 20372971.
24. Tong WG, Wierda WG, Lin E, Kuang SQ, Bekele BN, Estrov Z, Wei Y, Yang H, Keating MJ, Garcia-Manero G. Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics 5(6):499-508, 8/16/2010. e-Pub 8/16/2010. PMCID: PMC3322493.
25. Faderl S, Bueso-Ramos C, Liu Z, Pal A, Bornmann W, Ciurea DV, Harris D, Hazan-Halevy I, Kantarjian HM, Estrov Z. Kit inhibitor APcK110 extends survival in an AML xenograft mouse model. Invest New Drugs 29(5):1094-7, 10/2011. e-Pub 6/2010. PMID: 20517635.
26. Tong WG, Estrov Z, Wang Y, O'Brien S, Faderl S, Harris DM, Van Pham Q, Hazan-Halevy I, Liu Z, Koch P, Kantarjian H, Keating MJ, Ferrajoli A. The synthetic heat shock protein 90 EC141 induces degradation of the Bcr-Abl p190 protein and apoptosis of Philadelphia chromosome-positive acute lymphoblastic cells. Invest New Drugs 29(6):1206-12, 12/2011. e-Pub 6/2010. PMID: 20533075.
27. Hazan-Halevy I, Harris D, Liu Z, Liu J, Li P, Chen X, Shanker S, Ferrajoli A, Keating MJ, Estrov Z. STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood 115(14):2852-63, 4/8/2010. e-Pub 2/12/2010. PMCID: PMC2918366.
28. Bruey JM, Kantarjian H, Ma W, Estrov Z, Yeh C, Donahue A, Sanders H, O'Brien S, Keating M, Albitar M. Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia. Leuk Res 34(10):1320-4, 10/2010. e-Pub 4/1/2010. PMID: 20362333.
29. Li P, Harris D, Liu Z, Liu J, Keating M, Estrov Z. Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells. PLoS One 5(7):e11859, 2010. e-Pub 7/29/2010. PMCID: PMC2912280.
30. Ma W, Kantarjian H, Zhang X, Wang X, Estrov Z, O'Brien S, Albitar M. Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance. Leuk Res 35(4):526-33, 4/2011. e-Pub 10/2010. PMID: 20951430.
31. Jabbour E, Kantarjian H, Ravandi F, Garcia-Manero G, Estrov Z, Verstovsek S, O'Brien S, Faderl S, Thomas DA, Wright JJ, Cortes J. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 117(6):1236-44, 3/2011. e-Pub 10/2010. PMID: 20960519.
32. Manshouri T, Estrov Z, Quintás-Cardama A, Burger J, Zhang Y, Livun A, Knez L, Harris D, Creighton CJ, Kantarjian HM, Verstovsek S. Bone Marrow Stroma Secreted Cytokines Protect JAK2V617F-Mutated Cells From The Effects Of A JAK2 Inhibitor. Cancer Res 71(11):3831-40, 6/2011. e-Pub 4/2011. PMID: 21512135.
33. Mesa RA, Kantarjian H, Tefferi A, Dueck A, Levy R, Vaddi K, Erickson-Viitanen S, Thomas DA, Cortes J, Borthakur G, Pardanani AD, Estrov Z, Verstovsek S. Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement: Performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer 117(21):4869-77, 11/2011. e-Pub 4/2011. PMID: 21480207.
34. Liu Z, Hazan-Halevy I, Harris DM, Li P, Ferrajoli A, Faderl S, Keating MJ, Estrov Z. STAT-3 Activates NF-{kappa}B in Chronic Lymphocytic Leukemia Cells. Mol Cancer Res 9(4):507-15, 4/2011. e-Pub 3/2011. PMID: 21364020.
35. Chen Y, Cortes J, Estrov Z, Faderl S, Qiao W, Abruzzo L, Garcia-Manero G, Pierce S, Huang X, Kebriaei P, Kadia T, De Lima M, Kantarjian H, Ravandi F. Persistence of Cytogenetic Abnormalities at Complete Remission After Induction in Patients With Acute Myeloid Leukemia: Prognostic Significance and the Potential Role of Allogeneic Stem-Cell Transplantation. J Clin Oncol 29(18):2507-13, 6/2011. e-Pub 5/2011. PMID: 21555694.
36. Harris DM, Hazan-Haley I, Coombes K, Bueso-Ramos C, Liu J, Liu Z, Li P, Ravoori M, Abruzzo L, Han L, Singh S, Sun M, Kundra V, Kurzrock R, Estrov Z. Transformation of Human Mesenchymal Cells and Skin Fibroblasts into Hematopoietic Cells. PLoS One 6(6):e21250, 2011. e-Pub 6/2011. PMCID: PMC3120836.
37. Faderl S, Garcia-Manero G, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Gandhi V, Byrd AL, Kwari M, Cortes J, Kantarjian HM. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer 118(3):722-8, 2/1/2012. e-Pub 7/12/2011. PMID: 21751197.
38. Badoux X, Bueso-Ramos C, Harris D, Li P, Liu Z, Burger J, O'Brien S, Ferrajoli A, Keating MJ, Estrov Z. Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3. Hum Pathol 42(12):1989-2000, 12/2011. e-Pub 7/2011. PMID: 21733558.
39. Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, Burger J, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WG. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab (CFAR) for high-risk chronic lymphocytic leukemia. Blood 118(8):2062-8, 8/2011. e-Pub 7/2011. PMID: 21750315.
40. Naqvi K, Jabbour E, Bueso-Ramos C, Pierce S, Borthakur G, Estrov Z, Ravandi F, Faderl S, Kantarjian H, Garcia-Manero G. Implications of discrepancy in morphological diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood 118(17):4690-3, 10/2011. e-Pub 8/2011. PMID: 21868570.
41. Lee BN, Gao H, Cohen EN, Badoux X, Wierda WG, Estrov Z, Faderl SH, Keating MJ, Ferrajoli A, Reuben JM. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer 117(17):3999-4008, 9/2011. e-Pub 2/2011. PMID: 21858802.
42. Dimicoli S, Jabbour E, Borthakur G, Kadia T, Estrov Z, Yang H, Kelly M, Pierce S, Kantarjian H, Garcia-Manero G. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol 87(1):127-9, 1/2012. e-Pub 11/10/2011. PMID: 22072492.
43. Ohanian M, Leventaki V, Verstovsek S, Estrov Z, Lin P, Yin C, Kantarjian H, Huh Y, Ravandi F. Acute lymphoblastic leukemia arising in post - Polycythemic myelofibrosis, A rare entity. Leuk Lymphoma 53(9):1839-41, 9/2012. e-Pub 3/13/2012. PMID: 22303899.
44. Kadia TM, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, York S, Huang X, Pierce S, Brandt M, Koller C, Kantarjian HM, Ravandi F. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol 157(3):312-20, 5/2012. e-Pub 2/24/2012. PMID: 22360602.
45. Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi F. Phase II study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including post myeloproliferative neoplasms (MPN) acute myeloid leukemia (AML). Blood 119(20):4614-8, 5/17/2012. e-Pub 3/15/2012. PMID: 22422826.
46. Quintás-Cardama A, Kantarjian H, Estrov Z, Borthakur G, Cortes J, Verstovsek S. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res 36(9):1124-7, 9/2012. e-Pub 4/2/2012. PMID: 22475363.
47. Chen Y, Kantarjian H, Estrov Z, Faderl S, Ravandi F, Rey K, Cortes J, Borthakur G. A Phase II Study of Lenalidomide Alone in Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes With Chromosome 5 Abnormalities. Clin Lymphoma Myeloma Leuk 12(5):341-4, 10/2012. e-Pub 5/10/2012. PMID: 22579233.
48. Chacar C, Jabbour E, Ravandi F, Borthakur G, Kadia T, Estrov Z, Rios MB, Cortes J, Kantarjian H. Phase I-II Study of Bendamustine in Patients With Acute Leukemia and High Risk Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 12(3):197-200, 6/2012. PMID: 22578814.
49. Boumber Y, Kantarjian H, Jorgensen J, Wen S, Faderl S, Castoro R, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes J, Issa JP, Ravandi F. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia 26(11):2428-31, 11/2012. e-Pub 6/5/2012. PMID: 22665218.
50. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, Pierce S, Jabbour E, Borthakur G, Rumi E, Pungolino E, Morra E, Caramazza D, Cazzola M, Passamonti F. Long term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 120(6):1202-9, 8/9/2012. e-Pub 6/20/2012. PMID: 22718840.
51. Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gönen M, Estrov Z, Ebert BL, Chiosis G, Nimer SD, Bernstein BE, Verstovsek S, Levine RL. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 489(7414):155-9, 9/6/2012. e-Pub 7/2012. PMID: 22820254.
52. Ohanian M, Borthakur G, Quintas-Cardama A, Mathisen M, Cortes J, Estrov Z, Pemmaraju N. More Than Meets the Eye: Ocular Granulocytic Sarcoma: A Case Report and Literature Review. Clin Lymphoma Myeloma Leuk. e-Pub 9/2012. PMID: 23017332.
53. Benjamini O, Jain P, Estrov Z, Kantarjian HM, Verstovsek S. Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly. Blood 120(13):2768-9, 9/2012. PMID: 23019204.
54. Chen Y, Kantarjian H, Pierce S, Faderl S, O'Brien S, Qiao W, Abruzzo L, de Lima M, Kebriaei P, Jabbour E, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Cortes J, Ravandi F. Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia. e-Pub 11/8/2012. PMID: 23135353.
55. Bhamidipati PK, Jabbour E, Konoplev S, Estrov Z, Cortes J, Daver N. Epstein-Barr Virus-Induced CD30-Positive Diffuse Large B-Cell Lymphoma in a Patient With Mixed-Phenotypic Leukemia Treated With Clofarabine. Clin Lymphoma Myeloma Leuk. e-Pub 12/12/2012. PMID: 23246163.
56. Lamothe B, Lai Y, Hur L, Orozco NM, Wang J, Campos AD, Xie M, Schneider MD, Lockworth CR, Jakacky J, Tran D, Ho M, Dawud S, Dong C, Lin HK, Hu P, Estrov Z, Bueso-Ramos CE, Darnay BG. Deletion of TAK1 in the Myeloid Lineage Results in the Spontaneous Development of Myelomonocytic Leukemia in Mice. PLoS One 7(12):e51228, 2012. e-Pub 12/2012. PMID: 23251462.
57. Malik A, Shoukier M, Garcia-Manero G, Wierda W, Cortes J, Bickel S, Keating MJ, Estrov Z. Azacitidine in Fludarabine-Refractory Chronic Lymphocytic Leukemia: A Phase II Study. Clin Lymphoma Myeloma Leuk. e-Pub 12/19/2012. PMID: 23265768.
58. Rozovski U, Keating M, Estrov Z. The significance of spliceosome mutations in chronic lymphocytic leukemia. Leuk Lymphoma. e-Pub 12/28/2012. PMID: 23270583.
59. Jain P, Benjamini O, Lin P, Caraway NP, Landon G, Kim S, Shivaprasad S, Woodman K, O'Brien S, Ferrajoli A, Kadia T, Estrov Z. Central nervous system (CNS) Richter's transformation and parvovirus B19 infection. Leuk Lymphoma. e-Pub 1/2013. PMID: 23320889.
60. Nazha A, Estrov Z, Cortes J, Bueso-Ramos CE, Kantarjian H, Verstovsek S. Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. Leuk Lymphoma. e-Pub 1/2013. PMID: 23343175.
61. Jain P, Benjamini O, Konoplev S, Mohamed MS, Romo CG, Estrov Z. Spontaneous remission of chemo-immunotherapy related, non-transplant Epstein-Barr virus-associated lymphoproliferative disorder in a patient with chronic lymphocytic leukemia. Leuk Lymphoma. e-Pub 2/2013. PMID: 23387894.

Invited Articles

1. Stock, W, Estrov Z. Detection of minimal residual disease in acute lymphoblastic leukemia. UptoDate,, 2/2012.

Book Chapters

1. Estrov Z. The leukemia stem cell. Genetics, Biology and Therapy of Acute Myelogenous Leukemia. In: Cancer Treat Res. 145, 1-17, 2010. ISBN: 20306242.
2. Santos F, Hazan-Halevy I, Estrov Z. Targeting Signal Transducer and Activator of Transcription (STAT) for Anticancer Therapy. In: Cell Signaling & Molecular Targets in Cancer. Ed(s) M Chatterjee, K Kashfi. Springer: New York, NY USA, 299-321, 2012. ISBN: 978-1-4614-0729-4.

Grant & Contract Support

Title: Specialized Program of Research Excellence (SPORE) in Leukemia; Project 5: Development of Sapacitabine Therapy in Leukemias
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Hagop Kantarjian, MD
Duration: 9/1/2008 - 4/30/2013
Title: Role of STAT-3 serine phosphorylation in CLL
Funding Source: CLL Global Research Foundation
Role: Principal Investigator
Duration: 1/1/2006 - 5/31/2012

Last updated: 3/5/2013